Clinical trial
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT00513695
Study timeline
Study start (unknown)2007-06-01Date precision: month
Registry last updated2019-08-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Inflammatory Breast Cancerunresolved
Male Breast Cancerunresolved
Stage II Breast Cancerunresolved
Stage IIIA Breast Cancerunresolved
Stage IIIB Breast Cancerunresolved
Stage IIIC Breast Cancerunresolved
Interventions
sunitinib malateDRUG · verified · RxNorm: sunitinib malate
paclitaxelDRUG · verified · RxNorm: paclitaxel
doxorubicin hydrochlorideDRUG · verified · RxNorm: doxorubicin hydrochloride
cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
filgrastimBIOLOGICAL
therapeutic conventional surgeryPROCEDURE
flow cytometryOTHER
Sponsors & collaborators
University of Washingtonlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00513695 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.